New hope for stubborn blood cancers? tiny trial tests LSD1 blocker

NCT ID NCT04262141

Ongoing Disease control Sponsor: Terrence J Bradley, MD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests an experimental daily pill called IMG-7289 in 4 adults with essential thrombocythemia or polycythemia vera who did not improve on standard therapy. The drug targets the LSD1 protein to help control high blood cell counts. Researchers are checking whether it can improve blood counts and reduce symptoms, while monitoring for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMG-7289 (a daily oral capsule that blocks the LSD1 protein to help control blood cell counts)
What this could lead to: If it works, this could offer a new treatment option for people with these rare blood cancers who haven't responded to standard therapies.
What could go wrong: This is a very small early-phase trial with only 4 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL THROMBOCYTHEMIA POLYCYTHEMIA VERA

Contacts and locations

Locations

University of Miami

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.